
Adicet Bio Investor Relations Material
Latest events

Status Update
Adicet Bio

Q1 2025
6 May, 2025

Q4 2024
6 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adicet Bio Inc
Access all reports
Adicet Bio Inc. is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. The company specializes in creating off-the-shelf genetically modified gamma delta T cells that selectively target tumors, leveraging the unique properties of these cells to offer a new generation of immune cell therapy. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Key slides for Adicet Bio Inc


9th Annual CAR-TCR U.S. Summit
Adicet Bio Inc


Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
Adicet Bio Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ACET
Country
🇺🇸 United States